Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Pulmonology

Back to Medical Reference

Alpha 1-antitrypsin deficiency overview

Published: July 07, 2009. Updated: July 27, 2009

 

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Alpha 1-antitrypsin deficiency (A1AD) is a genetic disorder caused by reduced levels of alpha 1-antitrypsin in blood. It leads to pulmonary (lung) emphysema and, in severe cases, to liver disease.

Epidemiology

Northwest Europeans are at the highest risk for A1AD, with 4% carrying the PiZ allele and - therefore - a risk of homozygosity in about 1:625 to 1:2000.

Associated diseases

α1-antitrypsin deficiency has been associated with a number of diseases:

  • Asthma
  • Wegener's granulomatosis
  • Pancreatitis
  • Gallstones
  • Bronchiectasia (possibly)
  • Prolapse
  • Cancer
    • Hepatocellular carcinoma (liver)
    • Bladder carcinoma
    • Gallbladder carcinoma
    • Lymphoma
    • Lung cancer

Signs and symptoms

These are generally undistinguishable from the "normal" emphysema and cirrhosis.

Pathophysiology

Please refer to the alpha 1-antitrypsin for the various protease inhibitor (Pi) genotypes and phenotypes.

Normally, alpha 1-antitrypsin is produced in the liver and exists in levels of 1.5-3.5 gram/litre. When the levels are reduced (40-60%, in the PiSS, PiMZ and PiSZ phenotypes), most people will only suffer symptoms if they smoke, as the levels are still sufficient to counteract "normal" elastase activity in inflammation. Only in the PiZZ phenotype, when the levels are less than 15%, emphysema develops at a young age, and 50% will develop liver cirrhosis due to the accumulated protein, which is not secreted properly. On liver biopsy, they show as PAS-positive, diastase-negative granules.

Apart from increasing the inflammatory reaction in the airways, cigarette smoke also directly inactivates alpha 1-antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a rate of 2000.

Treatment

There is no specific treatment for A1AD; present management is identical for the "normal" treatment of emphysema and cirrhosis.

As ?1-antitrypsin is an acute phase reactant, its transcription is markedly increased during inflammation elsewhere in response to increased interleukin-1 and 6 and TNF? production. Any treatment that blunts this response, specifically paracetamol, can delay the accumulation of A1AD polymers in the liver and (hence) cirrhosis. A1AT patients are therefore encouraged to use paracetamol when slightly to moderately ill, even if they would otherwise not have used antipyretics.

Experimental therapies are aimed at the prevention of polymer formation in the liver.


Previous: Thyroid cancer Next: Asthma

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.